Neurocrine Biosciences, Inc. $NBIX Shares Bought by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC raised its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,667 shares of the company’s stock after acquiring an additional 209 shares during the period. Motley Fool Asset Management LLC’s holdings in Neurocrine Biosciences were worth $335,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of NBIX. Geneos Wealth Management Inc. boosted its stake in shares of Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares during the period. WPG Advisers LLC acquired a new stake in shares of Neurocrine Biosciences during the first quarter worth about $32,000. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Neurocrine Biosciences during the first quarter worth about $34,000. SVB Wealth LLC acquired a new stake in shares of Neurocrine Biosciences during the first quarter worth about $35,000. Finally, Golden State Wealth Management LLC boosted its stake in shares of Neurocrine Biosciences by 116.9% during the first quarter. Golden State Wealth Management LLC now owns 397 shares of the company’s stock worth $44,000 after buying an additional 214 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 106,322 shares of the stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $126.41, for a total value of $13,440,164.02. Following the completion of the transaction, the director directly owned 514,596 shares of the company’s stock, valued at approximately $65,050,080.36. This trade represents a 17.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Stock Down 1.0%

NASDAQ NBIX opened at $147.38 on Wednesday. The stock has a market capitalization of $14.62 billion, a P/E ratio of 43.60, a P/E/G ratio of 1.02 and a beta of 0.21. Neurocrine Biosciences, Inc. has a 52-week low of $84.23 and a 52-week high of $154.61. The firm has a 50-day moving average price of $140.54 and a 200 day moving average price of $128.79.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.46. The firm had revenue of $794.90 million during the quarter, compared to analysts’ expectations of $746.61 million. Neurocrine Biosciences had a net margin of 13.88% and a return on equity of 13.22%. The firm’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same period in the prior year, the company posted $1.81 earnings per share. On average, equities research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on NBIX shares. Morgan Stanley increased their target price on shares of Neurocrine Biosciences from $163.00 to $168.00 and gave the stock an “overweight” rating in a research note on Monday, October 20th. JPMorgan Chase & Co. increased their target price on shares of Neurocrine Biosciences from $140.00 to $145.00 and gave the stock a “neutral” rating in a research note on Thursday, July 31st. The Goldman Sachs Group started coverage on shares of Neurocrine Biosciences in a research note on Thursday, July 10th. They set a “buy” rating and a $182.00 target price for the company. Royal Bank Of Canada increased their target price on shares of Neurocrine Biosciences from $144.00 to $149.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Finally, Wall Street Zen upgraded shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 2nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $164.32.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.